BioventixLSE:BVXP 62 FCF Margin % is 70.37% as of Dec. 2025, which is 15% above its 10-year median of 61.00. GuruFocus rates LSE:BVXP with a GF Score™ of 62/100 and a GF Value™ of £35.80 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Bioventix ranks better than 97.81% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bioventix's Free Cash Flow for the
six
months ended in Dec. 2025 was £4.33 Mil. Bioventix's Revenue for the
six
months ended in Dec. 2025 was £6.16 Mil. Therefore, Bioventix's FCF Margin % for the quarter that ended in Dec. 2025 was 70.37%.
The historical rank and industry rank for Bioventix's FCF Margin % or its related term are showing as below:
LSE:BVXP'
s FCF Margin % Range Over the Past 10 Years
Min: 53.47 Med: 61 Max: 71.19
Current: 61.94
During the past 13 years, the highest FCF Margin % of Bioventix was 71.19%. The lowest was 53.47%. And the median was 61.00%.
LSE:BVXP's FCF Margin % is ranked better than 97.81% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs LSE:BVXP: 61.94
Bioventix FCF Margin % Related Terms
Bioventix FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bioventix's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BVXP vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Bioventix's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bioventix's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (LSE:BVXP) has a FCF Margin % of 70.37% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bioventix and its competitors. This is 15% above median its historical median of 61.00. Over the past decade, Bioventix's FCF Margin % has ranged from 53.47 to 71.19. According to the industry distribution chart, Bioventix ranks #21 out of 959 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Bioventix's FCF Margin % too high?
Bioventix's current FCF Margin % of 70.37% is 15% above median its 10-year median of 61.00. Over the past 10 years, this metric has ranged from a low of 53.47 to a high of 71.19. Based on the distribution chart, Bioventix ranks #21 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventix has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #21 out of 959 companies for FCF Margin %. This places Bioventix in the top 2% of its industry — outperforming the majority of peers. Historically, Bioventix's own FCF Margin % has ranged from 53.47 to 71.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bioventix and its competitors. Bioventix's current FCF Margin % is 70.37%, which is 15% above median its own 10-year median of 61.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (LSE:BVXP) is currently considered Significantly Undervalued. The stock's GF Value™ is £35.80, compared to a current price of £16.75 — trading 53.2% below its estimated fair value. The current FCF Margin % is 70.37%, which is 15% above median its 10-year median of 61.00. Bioventix's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bioventix (LSE:BVXP), the current FCF Margin % is 70.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (LSE:BVXP) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of £16.75 is trading 53.2% below its estimated GF Value™ of £35.80.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for LSE:BVXP:
FCF Margin %: 70.37% (15% above median its 10-year median of 61.00)
GF Value™: £35.80 vs. price of £16.75 (53.2% below fair value)
No single metric tells the full story. See the LSE:BVXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
62GF Score
Get the complete analysis for LSE:BVXP
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BVXP has been successfully added to your 
